DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Vision
  4. Research Highlights/News
  5. 2017 Vision Research Program

Vision

NEWS RELEASE

Released: February 3, 2017

Defense Health Program
Department of Defense Vision Research Program
Anticipated Funding Opportunities for Fiscal Year 2017

Due to the current Continuing Resolution, the Fiscal Year 2017 (FY17) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Vision Research Program (VRP), the VRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

FY17 VRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the VRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).


Award Mechanism PI Eligibility Key Mechanism Elements Funding
Clinical Trial Award Principal Investigators (PIs) must be at or above the level of Assistant Professor (or equivalent).
  • Preproposal is required; application submission is by invitation only.
  • Supports research with the potential to have a major impact on the treatment or management of visual injury and/or dysfunction.
  • The proposed intervention to be tested should offer significant potential impact for military Service members, Veterans, and other individuals living with visual dysfunction.
  • Funding from this award mechanism must support a clinical trial that is expected to begin no later than 12 months after the award date and should not be used for preclinical research studies.
  • Preliminary data supporting the proposed clinical trial are required.
  • Funded studies will be required to file the study in the National Institutes of Health (NIH) clinical trials registry, www.clinicaltrials.gov.
  • At the end of the period of performance, this work should show clear progress toward the next stage of implementation (i.e., Phase II clinical trials, U.S. Food and Drug Administration clearance for a medical device, etc.).
  • Maximum funding of $5.25M for total costs (direct and indirect costs)
  • Maximum period of performance is 4 years
Technology and Therapeutic Development Award PIs who are independent investigators at any level are eligible to submit applications.
  • Preproposal is required; application submission is by invitation only.
  • Supports the translation of promising preclinical findings into products for clinical applications, including detection, diagnosis, treatment, or quality of life. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and other individuals living with visual dysfunction.
  • The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics), device, or a knowledge-based product.
    • A �Knowledge Product� is a non-materiel product that addresses an identified need, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
  • The Principal Investigator (PI) must provide a transition plan showing how the product will progress to the next level of development after the completion of the VRP award.
  • Proof-of-concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established.
  • Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.
  • Maximum funding of $2.1M for total costs (direct and indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (htcdmrp.health.milmy.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Monday, December 16, 2024